Answers are grounded in this paper and cite their sources.
SARCLISA is an anti-CD38 therapy proven to deliver superior PFS (median PFS, 11.53 months with SARCLISA + Pd vs 6.47 months with Pd alone, HR=0.596, 95% CI: 0.44, 0.81, P=0.0010).SARCLISA also demonstrated a signifi cant increase in ORR (60.4% with SARCLISA + Pd [95% CI: 52.2%, 68.2%] vs 35.3% with Pd alone [95% CI: 27.8%, 43.4%], P<0.0001) 1 * Indication SARCLISA (isatuximab-irfc) is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Important Safety Information CONTRAINDICATIONSSARCLISA is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients. WARNINGS AND PRECAUTIONS Infusion-Related ReactionsInfusion-related reactions (IRRs) have been observed in 39% of patients treated with SARCLISA.All IRRs started during the fi rst SARCLISA infusion and resolved on the same day in 98% of the cases.The most common symptoms of an IRR included dyspnea, cough, chills, and nausea.The most common severe signs and symptoms included hypertension and dyspnea.
No takes yet. Share an insight, caveat, or question.
A 2020 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: